Home › Endometrial Cancer › Oregon
Endometrial Cancer clinical trials in Oregon
27 studies for Endometrial Cancer are looking for participants at sites in Oregon.
Cities in Oregon
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- and 1 more
RecruitingPhase 2
All ages · All sexes · Updated Oct 2, 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Oregon Health & Science University (OHSU), Portland
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- and 1 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 2, 2026 · NCT07198074A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 02, Portland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07814248Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 28, 2026 · NCT05112601Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Portland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Portland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06218914Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Providence Portland Medical Centre, Portland
- Providence Saint Vincent Medical Center, Portland
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT05640999A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Oncology Associates of Oregon, P.C. ( Site 8005), Eugene
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT06952504Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Providence Portland Medical Center, Portland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- Willamette Valley Cancer Institute and Research Center - Eugene, Eugene
- NW Cancer Specs. P.C., Happy Valley
- USOR - NW Cancer Specs P.C., Portland
- and 1 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 9, 2026 · NCT07166094A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Providence Cancer Institute of Oregon, Portland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06515613DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Eugene
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06989112Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Portland
RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Aug 21, 2026 · NCT05797168FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Oregon Health and Science University, Portland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05919264A Study of MGC026 in Participants With Advanced Solid Tumors
- Providence Cancer Institute, Portland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06242470Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Oncology Associates of Oregon, P.C., Eugene
- Compass Oncology - Rose Quarter, Portland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Oregon Health & Science University, Portland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT04657068Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Eugene
- Research Site, Portland
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 29, 2026 · NCT07044336Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #121, Portland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT06974110Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 517, Eugene
RecruitingPhase 2
Ages 18 and older · Women · Updated Jul 16, 2026 · NCT06906341First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Providence Cancer Institute Franz Clinic, Portland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT05768139cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Oregon Health Sciences University, Portland
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Jan 20, 2026 · NCT05366881Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
- Oncology Associates of Oregon, P.C., Eugene
- Northwest Cancer Specialists, P.C., Portland
RecruitingPhase 2
Ages 18 and older · Women · Updated Dec 24, 2025 · NCT06463028SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Portland
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- Oregon Health & Science University, Portland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Feb 13, 2025 · NCT05669430Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- Oncology Associates of Oregon, Eugene
- Northwest Cancer Specialists, Portland
RecruitingPhase 2/3
Ages 18 and older · Women · Updated May 2, 2024 · NCT05797831From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.